Although FCSL is not attending, we would like to highlight the following meeting.

Bispecific Antibody Congress, August 20-22, 2019
Washington, DC

Bispecific antibodies continue to show significant and impressive therapeutic value. While the development of bispecific antibodies is an evolving field, many challenges are still awaiting to be solved by experts in the field including target selection, better understanding of their mechanism of action, along with the combination selection of targets. This second annual  Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific development to improve your candidates’ translatability into the clinic.

.Included in these sessions are topics on

• Clinical progress for bispecifics and combinations
• Understanding the Biology for Enhanced Safety and Efficacy
• Case studies
• Immunogenicity and Pharmacology Considerations
• Engineerng innovations for Bi and Multi-Specific Platforms
• T-Cell Engagers

Speakers from AX, Genentech, Regeneron, Abbvie, Roche, Amgen, and Zymeworks, AstraZeneca.

For more information:  http://www.giiconference.com/chi778137/bispecific-antibody-design.shtml#Day1